All articles tagged with #george tidmarsh
The FDA is facing challenges in appointing a new head of its drug center following the abrupt departure of George Tidmarsh, with potential candidates like Richard Pazdur and Mary Thanh Hai declining the role, prompting the agency to open the position to internal staff.
The FDA is experiencing turmoil following the resignation of top regulator George Tidmarsh amid allegations of misconduct and criticism of its drug review process, reflecting broader instability within the HHS under Kennedy's leadership.
The FDA's top official for drugs, Dr. George Tidmarsh, resigned amid investigations into his personal conduct and a lawsuit alleging he made false statements and pursued vendettas against a pharmaceutical company's chair, highlighting ongoing leadership instability at the agency.
The top FDA drug regulator George Tidmarsh resigned amid an investigation and faced a federal lawsuit from Aurinia Pharmaceuticals, which alleges defamation and personal vendettas, with the lawsuit revealing incendiary texts and emails he sent to a former business associate.
George Tidmarsh, head of the FDA's Center for Drug Evaluation and Research, resigned amid ethics concerns and a lawsuit alleging bribery and false statements, following his administrative leave after raising issues about a drug approval program and questioning a drug's safety.
The FDA has appointed biotech veteran George Tidmarsh as the head of its drug regulation division amid ongoing regulatory upheaval under HHS Secretary Robert F. Kennedy Jr., with concerns over vaccine skepticism and drug approval processes.
The FDA has appointed biotech veteran George Tidmarsh as the director of its Center for Drug Evaluation and Research, bringing extensive experience in drug development, oncology, and pediatrics to the role.
The FDA is set to appoint former biotech executive George Tidmarsh as the new director of the Center for Drug Evaluation and Research, where he will oversee drug approvals and regulation amidst ongoing debates over accelerated approvals and advertising practices, bringing his industry experience to address controversial issues like opioid marketing and drug safety.
George Tidmarsh, a Stanford faculty member with extensive experience in drug development and clinical medicine, has been appointed as the new Director of the FDA's Center for Drug Evaluation and Research, where he will oversee efforts to ensure the safety and efficacy of drugs in the U.S.